Actavis' clients launch first generic Atorvastatin in Spain
(Thomson Reuters ONE) - Reykjavik, Iceland, 1 October 2009 -- Actavis Group, theinternational generic pharmaceuticals company, today announced thatits third-party sales division, Medis, has delivered 30 milliontablets of Atorvastatin to its clients in Spain. This is the firstgeneric version of the blockbuster molecule to reach the Spanishmarket.The product, Atorvastatin Magnesium, is launched by four of Spain'slargest generic pharmaceutical companies. Distribution of the productto Spanish pharmacies has already commenced.Atorvastatin efficiently regulates the blood cholesterol levels andis one of the most effective drugs used in the therapy of primaryhypercholesterolemia. Atorvastatin Magnesium is produced by Actavisin 10mg, 20mg and 40mg tablets. Pfizer, the originator, markets itsproduct in Spain under the brand names of Cardyl® and Zarator®.Atorvastatin's US brand name is Lipitor®.Atorvastatin tablets are subject to widely varying patent situationsaround the world, which is why Medis has invested significantly indifferent forms of the molecule. In Spain, the patent landscape isdifferent to other Western European markets, and the originatorproduct, containing Atorvastatin Calcium, is patented until 2010.Medis is currently promoting three different dossiers forAtorvastatin and has been supplying a product suitable for CentralEastern Europe for close to two years. Medis' alternative generic,Atorvastatin Magnesium, can be launched in Spain now, as it has beenapproved by the Spanish authorities. Medis has worked closely withits clients on the preparations for the launch.Actavis has already launched Atorvastatin Calcium under its own brandname in 15 countries in Europe and Asia where there was no patent.Atorvastatin Magnesium will be launched in Spain under Actavis' ownbrand name shortly.Annual sales of Cardyl® and Zarator® in Spain are approximately EUR396 million (2008, IMS Health). Atorvastatin is currently the topselling drug in Spain, and indeed the world.EnquiriesActavis GroupHjordis ArnadottirDirector - External CommunicationsTel: (+354) 535 2300 / 840 7476E-mail: harnadottir(at)actavis.comAbout Actavis GroupActavis is one of the world's leading generic pharmaceuticalcompanies specializing in the development, manufacture and sale ofgeneric pharmaceuticals. The company has operations in 40 countries,with 10,000 employees.Any statements contained in this press release that refer to Actavis'estimated or anticipated future results or future activities areforward-looking statements which reflect the Company's currentanalysis of existing trends, information and plans. Theseforward-looking statements are subject to a number of risks anduncertainties that could cause actual results to differ materiallydepending on factors such as the availability of resources, thetiming and effect of regulatory actions, the success of new products,the strength of competition, the success of research and developmentissues, unexpected contract breaches or terminations, exposure toproduct liability and other lawsuits, the effect of currencyfluctuations and other factors.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 01.10.2009 - 14:45 Uhr
Sprache: Deutsch
News-ID 6499
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 441 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actavis' clients launch first generic Atorvastatin in Spain"
steht unter der journalistisch-redaktionellen Verantwortung von
Actavis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
